WSW, NY, December 1st, 2025, FinanceWire
Pfizer’s multi billion dollar acquisition of Metsera (NASDAQ: MTSR) was more than a headline-grabbing obesity-drug deal. It was a signal. After a bidding war that pushed offers toward the $10 billion range, Pfizer may have reshaped how investors value next-generation metabolic therapies. The message was unmistakable: GLP-1 and multi-agonist drugs have become some of the most sought-after assets in pharmaceuticals, and Big Pharma is willing to pay extraordinary sums to secure future blockbusters.
Metsera’s near-$10 billion valuation has driven new interest in companies tied to emerging metabolic therapies, including Entera Bio (NASDAQ: ENTX). Entera is developing an oral tablet version of a GLP-1/glucagon–based peptide, giving it exposure to one of the fastest-growing areas in medicine. And because most metabolic drugs today require injections, the move toward a once-daily tablet could be a meaningful step in expanding patient access and adherence.
But the real advantage in Entera’s story is that GLP-1 exposure seems to only be one part of what investors can gain exposure to. Unlike many emerging biotechs built around a single obesity asset, Entera also has a late clinical-stage osteoporosis drug with a clear regulatory path and a validated oral-peptide platform powering multiple programs across large chronic-disease markets. In other words, Entera offers GLP-1 upside – and a pipeline aimed at some of the biggest unmet-need categories in medicine.
Beyond GLP-1: A Platform Already Validated in Humans
The excitement around GLP-1 medicines such as Eli Lilly’s (NYSE: LLY) Zepbound, and Novo Nordisk’s (NYSE: NVO) Wegovy and Rybelsus is grounded in enormous commercial demand. Rybelsus OASIS trials recently proved that oral semaglutide tablets can deliver robust weight-loss results and Novo Nordisk reportedly expects to expand its label to include obesity shortly. As a reference point, sales of Rybelsus in 2024 reached $3.4 billion solely based on its existing approvals in diabetes.
Entera participates in that trend through its oral GLP-1/Glucagon program, but its broader value proposition seems to come from the platform that makes oral peptides possible. Entera’s N-Tab technology is designed to stabilize peptides in the GI track and facilitate systemic absorption, offering a tablet format whereas most peptides require injections. Importantly, Entera’s platform already has human clinical validation in another enormous, under-deserved chronic condition – osteoporosis.
EB613: An Oral Anabolic for a 200-Million-Patient Disease
Osteoporosis affects an estimated 200 million women worldwide and causes millions of fractures each year. Some of the most effective treatments – especially anabolic drugs that build new bone and fix the skeleton – must be administered by injection, limiting adherence and use, especially in younger women at high risk of fracture. With more treatment options many fractures could be prevented. Medicare already spends $57 billion a year on fracture care (according to 2018 data) and as populations age globally, the clinical and economic burden of osteoporosis continues to rise.
Entera’s EB613 has been developed to create a new norm in osteoporosis treatment. It is an oral tablet candidate of Forteo – Eli Lilly’s blockbuster anabolic drug which requires daily injections and reached peak sales of around $2 billion, treating less than 10% of patients, before becoming generic in 2018. The premise is simple: if a proven bone-building treatment could be taken as a pill instead of a needle, many more patients might use it – and stick with it.
In a Phase 2 study in postmenopausal women with osteoporosis or low bone density, EB613 produced meaningful increases in bone mineral density (BMD) at the spine, hip, and femoral neck, along with dose-dependent improvements in bone-formation biomarkers at the 2.5 mg dose selected for Phase 3.
A key milestone for Entera came in late July 2025, when the FDA agreed that Entera may proceed with a single, placebo-controlled registrational Phase 3 trial using BMD as the primary endpoint for EB613 – which is unprecedented.
Historically, osteoporosis approvals required large, lengthy fracture-endpoint studies and to date, BMD can only be used as an endpoint for already approved drugs with existing fracture data or in a head to head bioequivalent format versus an active control. Thus, Entera’s unprecedented FDA alignment for EB613 is poised to significantly accelerate the timeline and reduce development risk.
If successful, EB613 could become the first and only oral anabolic osteoporosis tablet treatment positioned for a disease population comparable in scale to obesity but with far fewer competing therapies and substantial unmet need.
A Pipeline With Multiple Shots on Goal
EB613 is built on the same N-Tab platform that powers Entera’s other programs. EB612, another program by Entera, is being developed using another PTH(1-34) analogue to combat the rare endocrine disorder, hypoparathyroidism. Phase 2 studies using an earlier formulation of EB612 demonstrated clinically meaningful outcomes and robust pharmacokinetics (published JBMR 2021).
Entera also aims to advance an oral GLP-2 program, applying the N-Tab platform for gastrointestinal and intestinal-failure disorders. The only approved GLP-2 treatment today (Gattex, Takeda) requires daily injections. And in parallel, through its partnership with OPKO, Entera is co-developing a daily tablet of GLP-1/Glucagon , for obesity and fibrotic/metabolic diseases.
Together, these programs show that Entera is not a one-asset company but a pipeline of potential first in class oral peptides addressing major chronic conditions.
What the Metsera Deal Really Signals
Pfizer’s (NYSE: PFO) acquisition of Metsera does not predict Entera’s future. But it does seem to underscore the premium Big Pharma is now placing on differentiated therapies that can reshape chronic-disease treatment. Patent expirations, competitive pressure, and gaps in internal R&D pipelines are driving pharmaceutical companies to secure assets with the potential to become future blockbusters.
Entera, by contrast, remains relatively under the radar. As of late November 2025, its valuation sits around $109 million (as of the end of November 2025), with multiple shots on goal ahead.
Recent News Highlights From Entera Bio
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference
About Disclaimer & Disclosure: This content is a form of paid promotional content and advertising. Wall Street Wire receives cash compensation from Entera Bio Ltd Ltd for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available wallstwire.ai/disclosures. We are not responsible for any market size figures that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets or figures may exist that may not have been quoted. This article should not be considered an official communication by the issuer.